重度肾功能不全患者经适当选择后植入左心室辅助装置可行
研究假设经算法化术前优化后,重度肾功能不全患者植入LVAD不会增加并发症或死亡。结果显示两组1年生存率无显著差异(81% vs 86%,P = .98),结论认为经仔细选择的严重肾功能不全患者植入LVAD不增加中期并发症或死亡。
要点
- 术前优化(积极正性肌力药物和临时机械循环支持)可使部分低GFR患者GFR升至>30 mL/min/1.73 m2。
- 低GFR组与高GFR组1年生存率无显著差异(81% vs 86%,P = .98)。
- 术前GFR≤15 mL/min/1.73 m2的患者预防性启动临时肾脏替代治疗,亚组分析1年生存率与GFR≥60 mL/min/1.73 m2患者相同(89% vs 89%,P = .91)。
核心结论
- 经仔细选择的严重肾功能不全患者植入LVAD不增加中期并发症或死亡。
- 该策略可作为桥接移植或 destination therapy 的成功选择。
研究设计与样本
- 按术前GFR分为低GFR组(≤30 mL/min/1.73 m2,21例)和高GFR组(>30 mL/min/1.73 m2,37例)。
- 术前优化包括对急性肾功能不全成分的患者积极使用正性肌力药物和临时机械循环支持。
- 术前GFR≤15 mL/min/1.73 m2的患者术后预防性启动临时肾脏替代治疗。
- 主要结局为Kaplan-Meier 1年生存率。
主要发现
- 低GFR组中位Interagency Registry for Mechanically Assisted Circulatory Support评分显著更高,术前终末器官功能更差。
- 术前优化使低GFR组21例中11例GFR升至>30 mL/min/1.73 m2。
- 两组在正性肌力药物使用天数、呼吸机时间、重症监护室住院时间和总住院时间上无显著差异。
- 低GFR组1年生存率为81%,高GFR组为86%(P = .98)。
- GFR≤15 mL/min/1.73 m2亚组(n=11)与GFR≥60 mL/min/1.73 m2亚组(n=19)1年生存率相同(89% vs 89%,P = .91)。
关键数值与推荐
- 低GFR定义为术前GFR≤30 mL/min/1.73 m2,高GFR定义为>30 mL/min/1.73 m2。
- 术前GFR≤15 mL/min/1.73 m2的患者术后预防性启动临时肾脏替代治疗。
- 低GFR组1年生存率81%,高GFR组86%(P = .98)。
- GFR≤15 mL/min/1.73 m2亚组与≥60 mL/min/1.73 m2亚组1年生存率均为89%(P = .91)。
临床怎么用
- 对严重肾功能不全患者,可考虑经算法化术前优化后植入LVAD。
- 术前优化包括积极正性肌力支持和临时机械循环支持,以改善肾功能。
- 术前GFR≤15 mL/min/1.73 m2的患者术后可预防性使用临时肾脏替代治疗。
局限性
- 单中心经验,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Severe renal insufficiency is considered a relative contraindication to left ventricular assist device (LVAD) implantation. After establishing an algorithmic approach to these patients, we hypothesized that LVAD implantation with severe renal insufficiency could be performed without increasing morbidity or mortality. METHODS: All consecutive patients (July 2015-December 2017) who underwent LVAD implantation were retrospectively reviewed. Patients were stratified by preoperative glomerular filtration rate (GFR): ≤30 mL/min/1.73 m2 (low-GFR) and >30 mL/min/1.73 m2 (high-GFR). Preoperative optimization included aggressive inotropic support and temporary mechanical circulatory support before LVAD implantation in any patient with an acute component of renal insufficiency. All patients with a preoperative GFR ≤15 mL/min/1.73 m2 were prophylactically initiated on temporary renal replacement therapy postoperatively. The primary outcome was Kaplan-Meier 1-year survival. RESULTS: Fifty-eight patients (21 with low-GFR and 37 with high-GFR) were identified. Patients in the low-GFR cohort had a significantly higher median Interagency Registry for Mechanically Assisted Circulatory Support score and worse preoperative end-organ function. Preoperative optimization resulted in an increase in GFR to >30 mL/min/1.73 m2 in 11 out of 21 patients from the low-GFR cohort. Inotrope days, ventilator time, intensive care unit length of stay, and hospital length of stay were not significantly different between the groups. Kaplan-Meier 1-year survival was 81% in the low-GFR cohort and 86% in the high-GFR cohort (P = .98). Subset analysis of GFR ≤15 mL/min/1.73 m2 (n = 11) and ≥60 mL/min/1.73 m2 (n = 19) demonstrated identical 1-year survival (89% vs 89%; P = .91). CONCLUSIONS: LVAD implantation in carefully selected patients with severe renal insufficiency can be performed without increasing midterm morbidity or mortality. This strategy may serve as a successful option to bridge patients to transplantation or destination therapy.
引用
- Pasrija C, Tran D, George P, et al. Left ventricular assist device implantation may be feasible in appropriately selected patients with severe renal insufficiency. J Thorac Cardiovasc Surg. 2019. PMID: 31128896. doi:10.1016/j.jtcvs.2019.03.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。